Subscribe to MDT Magazine News

Angelini Labopharm Confirms Appointment of Mary Anne Heino as President

January 25, 2011 3:37 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., Jan. 25, 2011 /- Angelini Labopharm, LLC, today confirmed Mary Anne Heino's appointment as President of the Company.  Formerly Senior Vice President, Sales and Marketing for Labopharm Inc. and President of the company's wholly owned subsidiary, Labopharm USA, Inc.,...


Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma

January 25, 2011 3:37 am | by Bio-Medicine.Org | Comments

REDWOOD CITY, Calif., Jan. 25, 2011 /- Codexis, Inc. (Nasdaq: CDXS ) today announced the company's first biocatalysis collaboration in Japan, with Dainippon Sumitomo Pharma Co., Ltd. (DSP), one of the ten largest Japanese pharmaceutical manufacturers. Under the agreement, Codexis will...


AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar ...

January 25, 2011 3:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Jan. 25, 2011 /- AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes...


Chopin's hallucinations were probably caused by epilepsy

January 25, 2011 3:34 am | by EurekAlert | Comments

(BMJ-British Medical Journal) The composer Frederic Chopin, who regularly hallucinated, probably had temporal lobe epilepsy throughout his short life, reveals research published online in Medical Humanities. Hallucinations typically feature in seizure disorders, they say.

Mylan Announces Caduet® Settlement Agreement

January 25, 2011 3:33 am | by Bio-Medicine.Org | Comments

PITTSBURGH, Jan. 25, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that it has entered into a settlement agreement with Pfizer Inc. resolving litigation related to Caduet® Tablets, 2.5 mg/10, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg,...

Earnings Preview: WellPoint to report 4Q results

January 25, 2011 2:45 am | by The Associated Press | Comments

WellPoint Inc., the largest U.S. health insurer based on membership, reports fourth-quarter and full-year 2010 results Wednesday before the market opens.WHAT TO WATCH FOR: Rival UnitedHealth Group Inc. said last week its fourth-quarter profit jumped 10 percent as a drop in health care use...

Yaskawa develops SiC-based motor driving system for EVs

January 24, 2011 11:34 pm | by I-Micronews | Comments

Yaskawa Electric Corp developed the "SiC-QMET," a motor driving system for electric vehicles (EVs), by using a silicon carbide (SiC)-based power semiconductor device.

Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors

January 24, 2011 11:31 pm | by Bio-Medicine.Org | Comments

CAMBRIDGE, Mass., Jan. 25, 2011 /- Michael Porter, Ph.D., has joined the board of directors of Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer. (Photo:  ...


More and More Celebrities Are Embracing Hair Restoration

January 24, 2011 10:32 pm | by Bio-Medicine.Org | Comments

LONDON, Jan. 25, 2011 /- An interesting statistic: more than half (55%) of hair loss sufferers would be more inclined to consider having a hair transplant if celebrities or public figures were more open about hair restoration surgery, and men are more likely to be influenced than women...

Workers most invested in their jobs have highest stress levels, CAMH study shows

January 24, 2011 8:34 pm | by EurekAlert | Comments

(Centre for Addiction and Mental Health) A workplace's key employees may be at the greatest risk of experiencing high levels of work stress, according to a new study by the Centre for Addiction and Mental Health.

MSD Wellcome Trust Hilleman Laboratories announces first project

January 24, 2011 8:33 pm | by EurekAlert | Comments

(MSD Wellcome Trust Hilleman Laboratories) MSD Wellcome Trust Hilleman Laboratories announced that the organization's first project will be a feasibility study into how new technologies might be used to develop a rotavirus vaccine designed with developing country needs in mind....

Two Laser Balloon 'Live Cases' Shed New Light on Direct Visualization and PV Ablation

January 24, 2011 6:35 pm | by Bio-Medicine.Org | Comments

MARLBOROUGH, Mass., Jan. 24, 2011 /- CardioFocus announced that two "live cases" using its Endoscopic Ablation System were recently conducted. The first live case was a satellite transmission performed at Centro Cardiologico Monzino in Milan, Italy; broadcast to the 16th Annual Boston...


Summary Box: Amgen reports earnings, BioVex deal

January 24, 2011 1:45 pm | by The Associated Press | Comments

INFECTION DRUGS: Amgen Inc. said its profit rose 10 percent in the fourth quarter on better sales of its drugs Neulasta and Neupogen, which fight infections in patients on chemotherapy. Sales of the two drugs grew 3 percent to $1.24 billion.NEW PRODUCTS: Combined sales of its bone drugs Prolia and...

Novartis Offers $470M for Genoptix

January 24, 2011 1:34 pm | by San Diego Business Journal | Comments

The international pharmaceutical company Novartis AG said early Jan. 24 that it has agreed to buy Genoptix Inc., a Carlsbad-based specialty lab, for $470 million in cash.


Amgen 4Q profit up 10 percent on Neulasta sales

January 24, 2011 11:45 am | by The Associated Press | Comments

Biotechnology company Amgen Inc. says its profit rose 10 percent in the fourth quarter on better sales of anti-infection drugs and reduced taxes.The Thousand Oaks, Calif., company says its earned $1.02 billion, or $1.08 per share, from $931 million, or 92 cents per share. Excluding one-time...


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.